MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
uniQure
QURE
|
+$53.3M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$45.7M |
| 3 |
Liquidia
LQDA
|
+$34.2M |
| 4 |
Corvus Pharmaceuticals
CRVS
|
+$21.6M |
| 5 |
UroGen Pharma
URGN
|
+$17.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$33.1M |
| 2 |
Zai Lab
ZLAB
|
+$25.3M |
| 3 |
Compass Therapeutics
CMPX
|
+$17.8M |
| 4 |
Alkermes
ALKS
|
+$16.5M |
| 5 |
Vera Therapeutics
VERA
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q4 2025 Portfolio in Review
As of Q4 2025, MPM BioImpact held 55 positions worth $874M, up 43% from $611M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
MPM BioImpact deployed $99.1M of net new capital in Q4 2025, opening 15 new positions and adding to 6 existing holdings. Its largest new stake was uniQure: 1,381,628 shares worth $33.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $13.3M trimmed.
- MPM BioImpact's largest Q4 2025 buy was uniQure: 1,381,628 shares worth $33.1M.
- MPM BioImpact added most to Liquidia in Q4 2025, an estimated $34.2M increase.
- MPM BioImpact's biggest Q4 2025 reduction was Sarepta Therapeutics, cutting an estimated $13.3M.
- MPM BioImpact fully exited Avidity Biosciences in Q4 2025, selling an estimated $33.1M.
- MPM BioImpact's ten largest holdings make up 50% of its $874M portfolio in Q4 2025.
- MPM BioImpact opened 15 new positions and closed 17 in Q4 2025.
- MPM BioImpact's portfolio value rose 43% quarter-over-quarter to $874M.
Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.